CVM 最新10-Q变化
将 CVM 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-14 与上一份 10-Q · 2026-05-15
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +4 | −2 | ~14 | 67 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~3 | 0 |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):法律诉讼、风险因素
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-14
An “unmet (medical) need” is a factor for approval that is usually considered by all major regulatory bodies worldwide when assessing a product for commercial licensing. Despite some advances in treating patients with advanced primary squamous cell carcinoma of the head and neck there is still a sig…
Pembrolizumab (Keytruda) was approved only as a combination therapy – given as neoadjuvant (before surgery) and after surgery along with radiotherapy +/- chemotherapy and then long term. It was approved for perioperative use based on Event Free Survival only, not Overall Survival. Further, Keytruda …
Multikine could potentially increase that survival rate to over 70% in the patient population targeted in the confirmatory clinical trial of Multikine which is based on data obtained from the completed Multikine Phase III trial. In contrast to Keytruda, Multikine is given to newly diagnosed resectab…
During the nine months ended June 30, 2026, the Company’s cash decreased by approximately $4.4 million. The significant components of this decrease included net proceeds from the purchase of stock by officers and the June 2026 financing of $9.3 million offset by cash used to fund the Company’s regul…
相对上期删除的文字 · 来源:10-Q · 2026-05-15
During the six months ended March 31, 2025, 247,583 pre-funded warrants were exercised. No warrants were exercised during the six months ended March 31, 2026.
During the six months ended March 31, 2025, the Company’s cash decreased by approximately $2.8 million. Significant components of this decrease included net proceeds from the December 2024 and March 2025 financing of $6.7 million offset by cash used to fund the Company’s regular operations of approx…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议